Skip to main content
FRMSL logo

FRMSL — Investor Relations & Filings

Ticker · 4746 ISIN · TW0004746003 TW Manufacturing
Open in API
Filings indexed 1,872 across all filing types
Latest filing 2021-03-31 Capital/Financing Update
Country TW Taiwan
Listing TW 4746

About FRMSL

www.formosalab.com

Formosa Laboratories, Inc. is a Contract Development and Manufacturing Organization (CDMO) specializing in the development and production of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company provides integrated services ranging from process development and custom synthesis to large-scale commercial manufacturing. Its core product portfolio includes UV-filters, Vitamin D derivatives, and polymers such as cholesterol and phosphate binders. Formosa Laboratories offers specialized expertise in Antibody-Drug Conjugates (ADCs) and injectable manufacturing, including cytotoxic and freeze-dried products. Maintaining high quality standards, its facilities are cGMP-compliant and have been successfully inspected by the US FDA, TFDA, EDQM, and PMDA. The company serves a global clientele, providing one-stop solutions for complex chemical synthesis, fermentation, and peptide production.

Recent filings

Filing Released Lang Actions
代重要子公司台新藥股份有限公司公告現金增資已收足股款
Capital/Financing Update Classification · 95% confidence The document is a short announcement (676 characters) from a listed company (4746 台耀) reporting that its important subsidiary, 台新藥股份有限公司, has completed a cash capital increase with full payment received. The content focuses on the completion of a capital increase, specifying the number of shares issued, price per share, and total amount raised. There is no detailed financial report or analysis, just a factual update on a financing event. According to the definitions, this fits the category of Capital/Financing Update (CAP). The document is not a full financial report, nor an announcement of a report publication, but a direct update on capital structure changes.
2021-03-31 Chinese
109年第4季海外子公司投資
Interim / Quarterly Report Classification · 90% confidence The document contains detailed financial data related to investments in overseas subsidiaries, including investment amounts, shareholding percentages, and recognized investment gains or losses for a specific period (109th year, 4th quarter). The content is numerical and financial in nature, indicating it is part of a financial report rather than an announcement or summary. The document length is under 5,000 characters but contains substantive financial data, so it is not a mere announcement or certification. The data corresponds to a quarterly or interim period (4th quarter), which aligns with an Interim / Quarterly Report (IR). There is no indication that this is an Annual Report or Earnings Release, and it is not a regulatory filing or announcement. Therefore, the best classification is Interim / Quarterly Report (IR). FY 2020
2021-03-18 Chinese
109年度財務比率
Fund Information / Factsheet Classification · 90% confidence The document contains a financial data table summarizing key financial ratios and performance metrics for the company 台耀 over three fiscal years (107年度, 108年度, 109年度). The data includes financial structure, debt ratios, liquidity ratios, operational efficiency, profitability, and cash flow metrics. The document is relatively short (1002 characters) and presents summarized financial data rather than a full detailed report. It does not contain narrative management discussion, detailed financial statements, or comprehensive analysis typical of an Annual Report (10-K) or Interim Report (IR). It also does not appear to be an announcement or notice but rather a brief financial summary. This matches the description of a Fund Information / Factsheet (FS), which is a brief summary of key company facts and financials. Therefore, the best classification is FS with high confidence.
2021-03-18 Chinese
109年第4季大陸投資
Regulatory Filings Classification · 95% confidence The document is a tabular disclosure of investment amounts and related financial data concerning investments in mainland China by a Taiwanese listed company. It includes details such as capital amounts, investment methods, cumulative investment funds remitted, investment income, and regulatory approval limits. The document is short (1289 characters) and appears to be a regulatory disclosure of investment information rather than a full financial report or earnings release. There is no indication of it being an annual or interim report, audit report, or earnings release. It is not a meeting material, nor a voting result, nor a management change announcement. The content fits the profile of a regulatory filing providing specific investment disclosures as required by authorities. Therefore, the best classification is Regulatory Filings (RNS).
2021-03-18 Chinese
代重要子公司台新藥股份有限公司公告109年第一次現金增資 催繳股款公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (under 5,000 characters) from a listed company (台耀) regarding a cash capital increase payment reminder for its important subsidiary (台新藥股份有限公司). It details the deadline for payment and the consequences of non-payment, referencing company law articles. There is no financial statement, report, or detailed financial data presented. The document is an update on a capital increase event, specifically a reminder or notice about payment collection, which fits the category of Capital/Financing Update (CAP).
2021-03-12 Chinese
代重要子公司台新藥股份有限公司公告全體董監放棄認購增資 股數達二分之一以上，並洽特定人認購事宜
Capital/Financing Update Classification · 95% confidence The document is a short announcement (705 characters) from a listed company (台耀) regarding the waiver by directors and supervisors of subscription rights in a capital increase of a subsidiary. It details the number of shares waived and the authorization to negotiate with specific investors. There is no financial data, no detailed report, and no mention of a full report being attached or published. The content is about a capital increase and related subscription rights waiver, which fits the category of Capital/Financing Update (CAP). The document is not a full report but an update on financing activities.
2021-03-11 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.